MDSpire - Summary
From the Journals

GLP-1 Drugs Examined in Psychiatric Outcomes

Researchers evaluate mental health trajectories with antidiabetic therapies in patients with depression or anxiety.

Share

A recent Swedish study published in The Lancet Psychiatry reveals that semaglutide significantly lowers the risk of worsening mental illness in patients with depression or anxiety who are undergoing noninsulin antidiabetic therapy. Analyzing data from 95,490 patients over 5.2 years, findings indicate a 42% reduced risk of psychiatric hospitalization or self-harm when using semaglutide compared to nonuse periods. The research also noted that while liraglutide offered modest benefits, other GLP-1 receptor agonists like exenatide and dulaglutide showed no significant impact.

Original Source(s)

GLP-1 Drugs Examined in Psychiatric Outcomes

  • by Kathryn Wighton

  • March 26, 2026

Related Content

Trial Tests Single-Day TRD Treatment 

Randomized trial found more than half of treated patients achieved remission within 8 days.

Medical Oddities: When Men Face Catcalling

Cooking, catcalling, and colon swaps—medicine keeps things interesting.

Moral Distress Associated With Physician Burnout

Researchers link distress to burnout, professional fulfillment, and intent to leave or reduce clinical hours.